Abstract
A novel photonic suspension array has been developed for multiplex immunoassay. The carriers of this array were silica colloidal crystal beads (SCCBs). The codes of these carriers have characteristic reflection peaks originating from their structural periodicity; therefore they do not suffer from fading, bleaching, quenching or chemical instability. In addition, the fluorescence background of SCCBs is negligible because no fluorescence materials or dyes are involved. With a sandwich method, the proposed suspension array was used for simultaneous multiplex detection of heart failure (HF) and coronary heart disease (CAD) biomarkers in one test tube. The results showed that the three biomarkers: cardiac troponin I (cTnI), C-reactive protein (CRP) and B-type natriuretic peptide (BNP) could be assayed in the ranges of 0.1–500 ng/ml, 1–500 mg/L and 0.02–50 ng/ml with detection limits of 0.01 ng/ml, 0.36 mg/L and 0.004 ng/ml at 3σ, respectively. There were no significant differences between the photonic suspension array and traditional parallel single-analyte test. This novel method demonstrated acceptable accuracy, high detection sensitivity and reproducibility and excellent storage stability. This technique provides a new strategy for low cost, automated, and simultaneous multiplex immunoassays of bio-markers.
Highlights
Acute myocardial infarction (AMI) is a major and growing public health problem that frequently leads to irreversible heart failure (HF) and is a leading cause of death each year [1]
As the silica colloidal crystal beads (SCCBs) are derived from the assembly of mono-disperse colloidal nanopariticles in droplet templates, The surfaces of SCCBs and ordered hexagonal symmetry of the nano-particles were shown in figure 2A and 2B
To examine the high-throughput application of the photonic suspension array, we used the microscope equipped with a fiber optic spectrometer for SCCB decoding and immunoreactions
Summary
Acute myocardial infarction (AMI) is a major and growing public health problem that frequently leads to irreversible heart failure (HF) and is a leading cause of death each year [1]. The use of any single biomarker is not sufficient to accurately assess coronary heart disease (CAD) and HF. Multiplex immunoassay of biomarkers has attracted considerable interest to meet the growing demand for diagnostic applications in the process of CAD [7]. Multiplex immunoassays are advantageous because the offer higher sample throughput, less sample consumption, reduced turnaround times and a more reasonable cost compared to the traditional parallel single-analyte immunoassay [8]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
